{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"97"}]}],"title":"Participants Reporting At Least 1 AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"62"}]}],"title":"Adverse Events by Severity -Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"27"}]}],"title":"Adverse Events by Severity -Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"8"}]}],"title":"Adverse Events by Severity -Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}],"title":"Adverse Events by Severity -Life Threatening"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"18"}]}],"title":"AE Relationship to Study Drug -Not Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"11"}]}],"title":"AE Relationship to Study Drug-Probably Not Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"21"}]}],"title":"AE Relationship to Study Drug -Possibly Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"27"}]}],"title":"AE Relationship to Study Drug -Probably Related"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"20"}]}],"title":"AE Relationship to Study Drug -Definitely Related"}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"100"}],"units":"Participants"}],"description":"Number of participants with adverse events (AEs) collected from Day 1 (start of G-CSF mobilization) to the day before starting chemotherapy. AEs were graded by the investigator using the World Health Organization (WHO) Adverse Event Grading Scale and were assessed for severity (mild, moderate, severe, life-threatening) and relatedness to study treatment (5 point scale from 'not related' to 'definitely related').","groups":[{"description":"Participants with non-Hodgkin's lymphoma (NHL) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"Non-Hodgkin's Lymphoma"},{"description":"Participants with Hodgkin's disease (HD) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"Hodgkin's Disease"},{"description":"Participants with multiple myeloma (MM) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG002","title":"Multiple Myeloma"},{"description":"Participants with 'other' cancers (desmoplastic small round cell tumor, acute myeloid leukemia, and testicular cancer) were mobilized with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days. Plerixafor 240 µg/kg was given the evening of day 4 and G-CSF given the next morning followed by apheresis. Evening doses of plerixafor and morning doses of G-CSF followed by apheresis continued for up to a maximum of 7 aphereses or until ≥ 2\\*10\\^6 CD34+ cells/kg were collected.","id":"OG003","title":"Other Cancers"},{"id":"OG004","title":"All Patients"}],"paramType":"NUMBER","populationDescription":"Safety population of all participants who received at least 1 dose of plerixafor.","reportingStatus":"POSTED","timeFrame":"Day 1 to approximately day 38","title":"Overall Participant Counts Summarizing Adverse Events (AEs) During the Treatment Period","type":"PRIMARY","unitOfMeasure":"Participants"}